1. Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial 
Dr Hypolite Muhindo Mavoko, PhD, Carolyn Nabasumba, MD, Raquel Inocêncio da Luz, PhD, Halidou Tinto, PhD, Prof Umberto D'Alessandro, PhD, Andrew Kambugu, MD, Vito Baraka, MSc, Anna Rosanas-Urgell, PhD, Prof Pascal Lutumba, PhD, Jean-Pierre Van geertruyden, PhD 
The Lancet Global Health 
Volume 5, Issue 1, Pages e60-e68 (January 2017)
DOI: /S X(16)
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions

2. Figure 1
Trial profile for 28 days of follow-up after rescue treatment in QUINACT study participants at the Lisungi Health Centre (DR Congo) and the Kazo Health Centre (Uganda), 2012–14
The Lancet Global Health 2017 5, e60-e68DOI: ( /S X(16) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions

3. Figure 2
Nelson-Aalen PCR-adjusted estimates for rates of recurrent malaria infection in the modified intention-to-treat population in the re-treatment ACT group, Alternative ACT group, and quinine and clindamycin groups.
The Lancet Global Health 2017 5, e60-e68DOI: ( /S X(16) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions